Catalyst Pharmaceuticals, Inc.
CPRX
$24.49
$0.381.58%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 203.07% | 129.50% | 130.18% | -41.02% | -34.49% |
Total Depreciation and Amortization | 5.86% | 14.88% | 53.82% | 123.87% | 357.54% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -99.69% | -90.56% | -86.56% | 617.00% | 428.07% |
Change in Net Operating Assets | 260.10% | 182.83% | 199.59% | 120.24% | -519.65% |
Cash from Operations | 63.91% | 67.00% | 75.41% | 58.48% | 36.62% |
Capital Expenditure | 99.02% | 99.72% | 77.49% | 78.90% | 78.91% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | 97.60% | -1,062.48% | -593.70% |
Cash from Investing | 99.73% | 99.81% | 84.80% | 19.17% | 14.25% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -88.35% | 5,434.20% | 2,715.55% | 1,503.37% | 1,364.01% |
Repurchase of Common Stock | -55.99% | 31.98% | 11.10% | 11.10% | 86.00% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 2.21% | -4.07% | -4.00% | -519.48% | -861.79% |
Cash from Financing | -97.94% | 1,395.62% | 1,807.61% | 2,029.20% | 3,731.56% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 66.65% | 336.33% | 337.88% | 712.94% | 638.30% |